International Delegations Gain Visibility and Recognition at RESI

8 Dec

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

RESI JPM San Francisco will once again be a showcase for cutting edge technologies from distant regions of the globe. Because the RESI conference draws top life science investors and strategic partners, regional technology hubs see it as a chance to give their constituents direct access to funding opportunities and expansion into new markets.

Previous delegations from places including Korea, Quebec, Chile, Taiwan, Israel, Ontario and France have used RESI as a springboard for their companies. And this upcoming RESI JPM San Francisco 2023 will be no exception.

This RESI, the Israel Economic Mission to the West Coast, USA, and the Israel Export Institute are proud to showcase some of the companies making waves in the digital health field. They include companies with innovative technology focused on AI, Machine Learning, Voice Recognition, Big data, AR/ VR, Robotics, with disruptive solutions for Diagnostics Digital Imaging, Precision Medicine, Decision Support Systems, Clinical Workflow Management, Telemedicine, Remote Monitoring, and Smart Surgical Equipment, and many more.

Likewise, the Brisbane Economic Development Agency is sponsoring a cohort of hot MedTech and Digital Health companies from the Australian state of Queensland to come to San Francisco and showcase the technologies being developed in that part of the world that will have an impact everywhere. The members of the cohort have participated in a custom 2-month long educational program together with Life Science Nation that will culminate in San Francisco, where they will be well prepared to pitch and partner with global life science players.

Be sure to check out these technologies in the Innovator’s Pitch Challenge poster board section at RESI and say hello to their founders. They’ll be happy to tell you their stories.

RESI-SF-2023-Banner-1100-wide

Hot Investor Mandate: Firm Founded By Established VC Seeks Promising Medical Device & Diagnostics Companies Across the Globe, Investing Up to $10M

8 Dec

Recently founded by a leading venture capital firm, this new firm is interested in investing in and establishing strategic partnerships with innovative medtech companies. The firm is looking for domestic and cross-border partnerships in terms of equity investment, license-in, distribution and others. The firm can invest anywhere from hundreds of thousands to 10MM USD, and is open to both leading and co-investing. The firm looks for opportunities globally.

The firm focuses on all classes of medical devices, including PMA, 510k and software enabled devices, all the way from in-development to commercialization stage. The firm is also interested in diagnostics/monitoring devices, PMA and 510k diagnostics technologies. The firm looks for truly innovative technologies. Interested indications include but are not limited to minimally invasive surgical devices, neurology, oncology, ophthalmic, dental, urology, GI and ENT.

The firm has no specific requirement for the company and its management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm Invests in Seed and Early Venture Rounds, Investing Broadly Across All Life Science Sectors and Focusing on USA-Based Opportunities

8 Dec

A life-sciences focused venture capital firm currently making investments into US-based companies out of its fourth fund primarily makes equity investment into seed and early stage rounds ranging from $250,000 to $1 million initially and up to $2 million over the lifetime of the investment.  The firm could make as many as 3 new investments over the next 6-9 months.

The firm is looking for U.S. companies in sectors of Therapeutics, Diagnostics, Medical Devices, Life Science Tools and digital health. The firm is agnostic in terms of subsectors and indications within these areas and is also interested in orphan indications and wireless medical devices. The firm looks to invest in early-stage companies including pre-clinical stage companies with some supporting in-animal data, although it is not a requirement.

The firm is looking for privately held companies with experienced management teams. The firm looks to play an active role as an investor and generally looks to take a board or board observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Impact Investment Evergreen Fund Actively Invests in All Life Science Technologies Relevant to Oncology Indications

8 Dec

An impact investment arm of a non-profit organization manages an evergreen fund and is interested in therapeutics, diagnostics or screening technology, medical devices, digital health or tech enabled services that align with the firm’s mission to advance the fight against cancer. The firm will invest in companies of all stages of development (excluding public companies), and looks for companies that are advancing science, reducing disparities, and promoting health care sustainability; though there is a preference for Seed and Series A stage companies. The firm’s typical check size ranges from $250K-$2 million per round and reserves additional funds for follow-on investments. The firm is currently looking to co-invest, and will consider global opportunities, but is currently investing mostly in the US.

While relatively agnostic to technology within therapeutics, medical devices, diagnostics and digital health, The firm will only invest in companies relevant to the indication of oncology.

The firm is looking to co-invest in private companies only.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based VC Invests In Software-Based, Data-Driven Life Science and Healthcare Technologies With a Focus on North America Companies

8 Dec

A USA-based firm is investing from its second fund and manages about $150M AUM. The firm invests in pre-seed through Series A rounds in exchange for equity. Typical allocations average in the $500k to $1.5M range. The main areas of interest for the firm are data-driven healthcare/biotech, enterprise software, and deep tech. The firm tends to focus on companies headquartered in North America.

The firm invests in software and hardware with proprietary algorithmic and design principles. For example, big data, AI/ML, robotics, and autonomous vehicles are of interest. Within data-driven health/biotech, the firm focuses on core technology innovations in computational health, synthetic biology, and digital health. Their portfolio includes companies involved in deep learning for medical imaging, genomics platforms and tools, in silico therapeutics discovery, large scale custom DNA synthesis, and a digital health platform consisting of software and integrated wearable hardware.

The firm seeks to work with management teams that have prior entrepreneurial experience or domain-specific technical or medical experience in the market they are targeting. They typically have regular check-ins with portfolio companies and can take on board seats.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Bridging the Gap between Academia and Industry

6 Dec

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

Mansfield Bio-Incubator Chief Operating Officer, Alexander Margulis has been in the Life Sciences industry for over 20 years and is passionate about creating a robust and accessible entrepreneurial community among local universities, startups, and investors. Less than 1-hour away from Boston and Cambridge, the facility provides affordable private and shared spaces for research labs, mentorship and networking opportunities. In addition, they offer several resources such as access to professional advisors and assistance with government and private funding research applications. Currently, Mansfield Bio-Incubator hosts over 20 early-stage startups ranging from therapeutics, medical devices, and cleantech in the life sciences areas of oncology, women’s health, animal health, biomaterials, water purification, and more.

Listen to our conversation to learn more about how Alexander and his team are creating, growing, and ensuring the success of the next generation of life science companies at Mansfield Bio-Incubator.

Digital RESI March 2023 Email Banner.(NEWtouse)

Vessl Prosthetics at RESI

1 Dec

By Rikki Piccirillo, Marketing Manager, LSN

RikkiCo-Founders, Sydney Robinson and Oleksiy Zaika of Vessl Prosthetics joined us at RESI Boston in September. With an understanding of the value of building relationships early in their fundraising journey, attending RESI made perfect sense. This team made the most of their time at RESI, researching attending investors, strategizing panel attendance, and capitalizing on every learning and networking opportunity that presented itself. As thorough and prepared as they were for their time at RESI, the same zest can be said for how Vessl Prosthetics came to be. In this interview with Sydney, you can learn more about their company, the product their developing and their strategy at RESI:

Registration is open for RESI JPM San Francisco, January 10 In Person at the Marines’ Memorial Club & Hotel & January 11-12 online Virtual Partnering.

RESI-SF-2023-Banner-1100-wide

← Older Entries
Newer Entries →